1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Marizyme, Inc.

Marizyme, Inc.

MRZM
Marizyme, Inc.US flagOther OTC
0.00
USD
- -
- -
39,538.00Market Cap
2012 Y
2012 Y
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
TTM
Revenue per Share
37.28
0.05
- -
- -
0.37
0.26
0.09
- -
- -
0.01
0.01
0.01
0.01
- -
Basic EPS, GAAP
-14.76
-2.57
-2.31
-9.37
-8.22
-0.79
-0.52
-0.04
-0.05
-0.22
-0.31
-0.94
-1.53
-0.17
Free Cash Flow per Basic Share
-10.62
-7.13
1.94
-0.68
-0.14
0.15
-0.61
-0.03
-0.01
-0.13
-0.16
-0.27
-0.1
-0.03
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
-15.11
-1.89
-4.2
-6.27
-15.52
-23.74
-25.08
-4.48
-1.56
-1.39
-1.33
-2.11
-3.42
-1.29
Tangible Book Value per Share
-11.91
24.8
21.18
10.62
2.53
2.5
1.97
- -
-0.01
0.11
-0.34
-0.43
-0.58
-0.27
Basic Weighted Avg Shares
1
1
1
1
1
1
1
7
20
26
36
41
45
132
Sales/Revenue/Turnover
32
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
1
- -
Operating Margin (%)
-32.1
-6,323.53
- -
- -
-292.05
-62.45
-123.46
-1,224.2
- -
-2,941.93
-4,195.09
-5,556.59
-3,072.44
-6,741.22
Depreciation Expense
6
- -
- -
- -
- -
- -
- -
- -
- -
1
- -
1
1
1
Net Income, GAAP
-13
-3
-2
-10
-9
-1
-1
- -
-1
-6
-11
-38
-70
-22
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
-39.6
-5,659.7
- -
- -
-2,219.24
-299.76
-563.88
-1,232.19
- -
-2,964.99
-5,230.16
-16,346.18
-10,767.77
-12,007.82
Working Capital
-11
10
7
3
1
- -
- -
- -
- -
2
1
-1
-22
-29
LT Debt
3
4
- -
- -
- -
- -
- -
- -
- -
1
1
4
1
- -
Total Equity
44
25
23
13
4
3
2
29
28
45
48
17
-7
-16
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -

Capital Structure

FRC

•

in mil. unless spec.
Mar'24
Jun'24
Sep'24
ST Debt
23
20
26
LT Borrowings
- -
- -
- -
LT Finance Leases
1
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
132
132
132
Market Capitalization
7
6
7

Working Capital

FRC

•

in mil. unless spec.
Mar'24
Jun'24
Sep'24
Total Current Assets
1
1
1
Cash, Cash Equivalents & STI
- -
- -
- -
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
26
24
30
Payables & Accruals
3
4
4
ST Debt
23
20
26
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
92%
-27.53%
-138.46%
Free Cash Flow
165.08%
531.42%
-56.83%
Net Income, GAAP
132.34%
239.04%
82.2%
Sales/Revenue/Turnover
- -
- -
176.6%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2022
- -
- -
- -
- -
- -
2023
- -
- -
- -
- -
1
2024
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2022
-0.15
-0.17
-0.04
- -
-0.94
2023
-0.06
-0.48
-0.58
- -
-1.53
2024
-0.05
-0.03
-0.01
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2022
- -
- -
- -
- -
- -
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -

Company Description

APIChat
CEO
David L. Barthel
Full Time Employees
13
Sector
Healthcare
Industry
Biotechnology
Address
555 Heritage Drive Jupiter FL United States of America 33458
IPO Date
Nov 10, 2010
CIK
0001413754
Website
marizyme.com
Similar Companies
Q BioMed Inc. (QBIO)
Moderna, Inc. (0QF.F)
RepliCel Life Sciences Inc. (RP.V)
MorphoSys AG (MOR.DE)
D&D Pharmatech (347850.KQ)
AveXis, Inc. (AVXS)
Business
Marizyme, Inc. Marizyme, Inc. (MRZM) operates as a multi-technology life sciences company focused on the research, development, acquisition, and commercialization of innovative medical devices, diagnostics, and therapies targeting unmet needs in cardiac care, surgical applications, and chronic disease management. The company offers DuraGraft, a flagship biocompatible intraoperative vascular graft storage and flushing solution that preserves endothelial function during coronary artery bypass graft (CABG) surgery to reduce graft failure and related complications; Krillase, a patented protease complex derived from Antarctic krill enzymes used for biofilm removal, wound debridement, skin grafting, and veterinary plaque reduction in dogs and cats; and MATLOC 1, a point-of-care lab-on-a-chip digital device under development for screening individuals at risk of chronic kidney disease via microfluidic analysis with mobile data transfer. Marizyme conducts operations in the United States, Europe, and Asia, with headquarters in Jupiter, Florida, where it was founded in 2018 following key acquisitions including Krillase technology in September 2018, Somahlution assets in July 2020, and My Health Logic Inc. in December 2021. Recent developments include a co-marketing agreement with Qualigen Therapeutics, Inc. in 2024 and a non-binding memorandum of understanding dated March 28, 2025, for Qualigen's potential acquisition of Marizyme to accelerate DuraGraft commercialization and revenue generation targeted for late fiscal 2025, pending due diligence and shareholder approval.

Company News

APIChat

  • globenewswire.com

    Marizyme Enters Into Co-Development Agreement With Qualigen Therapeutics for the Commercialization of FDA-Cleared DuraGraft™

  • globenewswire.com

    Marizyme CEO Delivers Business Update

  • globenewswire.com

    Marizyme, Inc. Announces FDA Clearance for Flagship Product, DuraGraft™

  • seekingalpha.com

    U.S. IPO Weekly Recap: The IPO Market's Micro-Cap Run Continues With 2 Small Healthcare Deals

  • globenewswire.com

    Marizyme is Pleased to Announce the Appointment of David Barthel as CEO

  • prnewswire.com

    Marizyme, Inc. Issues Letter to Shareholders

  • prnewswire.com

    Marizyme Announces New Distribution and Channel Partnership for Chilean Market with Abdera

  • prnewswire.com

    Marizyme, Inc. Strengthens Senior Management Team with Two Appointments: Roger Schaller EVP, Commercial Operations and Amy Chandler, EVP, Regulatory Affairs and Quality Management Systems

  • prnewswire.com

    Marizyme Announces Approval for DuraGraft® in India

  • prnewswire.com

    Marizyme Announces the Use of DuraGraft® as the Standard-of-Care in Patients Undergoing Coronary Artery Bypass Surgery (CABG) at Vienna Heart Center North Floridsdorf